Integral Diagnostics Ltd. (AU:IDX) has released an update.
Integral Diagnostics is set to merge with Capitol Health, creating a diagnostic imaging leader in ANZ with a combined revenue and EBITDA of approximately $651 million and $93 million, respectively. The deal, which is projected to deliver double-digit earnings per share growth for Integral shareholders by FY25, has been unanimously recommended by Capitol’s Board. The merger aims to enhance clinical outcomes, drive productivity with AI technology, and achieve at least $10 million in annual pre-tax net cost synergies, with most savings expected within the first year.
For further insights into AU:IDX stock, check out TipRanks’ Stock Analysis page.
